brimarafenib   Click here for help

GtoPdb Ligand ID: 13203

Synonyms: compound 1.49 [WO2014206343]
Compound class: Synthetic organic
Comment: The chemical structure for brimarafenib was obtained from proposed INN list 130 (Feb. 2024). The INN is described as Raf kinase inhibitor and antineoplastic agent. This structure matched to PubChem CID 117807031 and to compound 1.49 claimed in BeiGene patent WO2014206343 [1]. Based on BeiGene's disclosed pipeline we suspect that brimarafenib is their clinical lead BRAF inhibitor BGB-3245.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 101.05
Molecular weight 482.41
XLogP 0.2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=C(C=C2C(=C1)O[C@H]3[C@@H]2[C@@H]3NC(=O)NC4=CC(=C(C=C4F)F)F)OC5=CC=NC6=C5CCC(=O)N6
Isomeric SMILES O=C1CCC=2C(=CC=NC2N1)OC=3C=CC4=C([C@@H]5[C@H](O4)[C@H]5NC(=O)NC6=C(C=C(C(=C6)F)F)F)C3
InChI InChI=1S/C24H17F3N4O4/c25-13-8-15(27)16(9-14(13)26)29-24(33)31-21-20-12-7-10(1-3-17(12)35-22(20)21)34-18-5-6-28-23-11(18)2-4-19(32)30-23/h1,3,5-9,20-22H,2,4H2,(H,28,30,32)(H2,29,31,33)/t20-,21-,22-/m0/s1
InChI Key USMWOBMHNWNPAP-FKBYEOEOSA-N
No information available.
Summary of Clinical Use Click here for help
BGB-3245 is a therapeutic lead for cancer treatment.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04249843 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Phase 1 Interventional MapKure, LLC
NCT05580770 Mirdametinib + BGB-3245 in Advanced Solid Tumors Phase 1/Phase 2 Interventional SpringWorks Therapeutics, Inc. Link to our record for .
NCT06194877 A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers Phase 1 Interventional MapKure, LLC Link to our record for .